Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma

Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma
Atlanta, GA (PRWEB) May 06, 2015 Histogen, Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, will present new research on its 105F immunomodulatory treatment candidate for melanoma during the 2015 Society of Investigative Dermatology (SID) Annual Meeting, taking place May 6-9, 2015 in Atlanta, GA. ...